64 related articles for article (PubMed ID: 20585086)
1. Role of cetuximab in the treatment of patients with NSCLC: are we throwing out the baby with the bath water?
Floriani I; Garassino MC; Broggini M; Veronese S; Marsoni S; Marabese M; Farina G; Scanni A
J Clin Oncol; 2010 Sep; 28(27):e467; author reply e468. PubMed ID: 20585086
[No Abstract] [Full Text] [Related]
2. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
Buikhuisen WA; Burgers JA; Vincent AD; Schellens JH; Beijnen JH; Smit EF; Joerger M
J Clin Oncol; 2010 Sep; 28(27):e482-3; author reply e484. PubMed ID: 20606096
[No Abstract] [Full Text] [Related]
3. Adjuvant chemotherapy for non-small-cell lung cancer: a fading effect?
Besse B; Le Chevalier T
J Clin Oncol; 2008 Nov; 26(31):5014-7. PubMed ID: 18809602
[No Abstract] [Full Text] [Related]
4. New agents in advanced non-small-cell lung cancer treatment.
Ricciardi S; de Marinis F
Oncology; 2009; 77 Suppl 1():103-12. PubMed ID: 20130438
[TBL] [Abstract][Full Text] [Related]
5. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
Lynch TJ; Patel T; Dreisbach L; McCleod M; Heim WJ; Hermann RC; Paschold E; Iannotti NO; Dakhil S; Gorton S; Pautret V; Weber MR; Woytowitz D
J Clin Oncol; 2010 Feb; 28(6):911-7. PubMed ID: 20100966
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel-carboplatin chemotherapy combined with cetuximab in patients with locally advanced or metastatic non small-cell lung cancer (NSCLC)--results of the nonrandomised phase II study TaxErb.
Fischer JR; Griesinger F; Fink T; Salm T; Marseille A; Wolf M
Lung Cancer; 2012 Mar; 75(3):348-52. PubMed ID: 21908069
[TBL] [Abstract][Full Text] [Related]
7. [Combination chemotherapy for treatment of metastasing non-small-cell lung carcinoma. Monotherapy of combinations of two or three agents--a survey of a Cochrane review].
Mellemgaard A; Pappot H
Ugeskr Laeger; 2009 Jun; 171(25):2084-7. PubMed ID: 19671386
[No Abstract] [Full Text] [Related]
8. Emerging profile of cetuximab in non-small cell lung cancer.
Ettinger DS
Lung Cancer; 2010 Jun; 68(3):332-7. PubMed ID: 19783064
[TBL] [Abstract][Full Text] [Related]
9. Pemetrexed plus bevacizumab for second-line therapy of non-small-cell lung cancer: the importance of patient selection.
Araujo AM
J Clin Oncol; 2010 Mar; 28(8):e131; author reply e132. PubMed ID: 20100954
[No Abstract] [Full Text] [Related]
10. Cetuximab-based therapy is effective in chemotherapy-naïve patients with advanced and metastatic non-small-cell lung cancer: a meta-analysis of randomized controlled trials.
Ibrahim EM; Abouelkhair KM; Al-Masri OA; Chaudry NC; Kazkaz GA
Lung; 2011 Jun; 189(3):193-8. PubMed ID: 21424607
[TBL] [Abstract][Full Text] [Related]
11. [Therapeutic strategies in advanced non-small cell bronchial cancers: combinations without platin drugs].
Postmus P
Rev Pneumol Clin; 2002 Nov; 58(5 Pt 2):3S48-50. PubMed ID: 12538936
[No Abstract] [Full Text] [Related]
12. Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.
Pirker R; Pereira JR; Szczesna A; von Pawel J; Krzakowski M; Ramlau R; Vynnychenko I; Park K; Eberhardt WE; de Marinis F; Heeger S; Goddemeier T; O'Byrne KJ; Gatzemeier U
Lung Cancer; 2012 Aug; 77(2):376-82. PubMed ID: 22498112
[TBL] [Abstract][Full Text] [Related]
13. Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.
Krug LM; Miller VA; Patel J; Crapanzano J; Azzoli CG; Gomez J; Kris MG; Heelan RT; Pizzo B; Tyson L; Sheehan C; Ross JS; Venkatraman E
Cancer; 2005 Nov; 104(10):2149-55. PubMed ID: 16208701
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy helps patients with advanced non-small cell carcinoma of the lung.
Socinski MA; Detterbeck FC; Rivera MP; Egan TM; Halle J; Rosenman J
N C Med J; 1996; 57(5):281-6. PubMed ID: 8854691
[No Abstract] [Full Text] [Related]
15. Adjuvant chemotherapy for surgically resected non-small cell lung cancer.
Heon S; Johnson BE
J Thorac Cardiovasc Surg; 2012 Sep; 144(3):S39-42. PubMed ID: 22502967
[TBL] [Abstract][Full Text] [Related]
16. Patient selection criteria and the FLEX Study.
Herbst RS; Hirsch FR
Lancet; 2009 May; 373(9674):1497-8. PubMed ID: 19410696
[No Abstract] [Full Text] [Related]
17. HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.
Cappuzzo F; Bemis L; Varella-Garcia M
N Engl J Med; 2006 Jun; 354(24):2619-21. PubMed ID: 16775247
[No Abstract] [Full Text] [Related]
18. [A phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non squamous, non-small cell lung cancer (NSCLC)].
Tredaniel J; Mornex F; Barillot I; Diaz O; Hennequin C; Le Pechoux C; Lavole A; Giraud P; Souquet PJ; Teixeira L; Vaylet F; Zalcman G; Baudrin L; Morin F; Milleron B
Rev Mal Respir; 2011 Jan; 28(1):51-7. PubMed ID: 21277474
[TBL] [Abstract][Full Text] [Related]
19. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer.
Thienelt CD; Bunn PA; Hanna N; Rosenberg A; Needle MN; Long ME; Gustafson DL; Kelly K
J Clin Oncol; 2005 Dec; 23(34):8786-93. PubMed ID: 16246975
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab for non-small-cell lung cancer.
Garassino MC; Hollander L; Torri V
N Engl J Med; 2007 Mar; 356(13):1373; author reply 1374-5. PubMed ID: 17392310
[No Abstract] [Full Text] [Related]
[Next] [New Search]
